In a study presented at the 25th international Aids conference in Munich on Tuesday, experts calculated that the minimum price for mass production of a generic version, based on the costs of lenacapavir’s ingredients and manufacturing, and allowing for 30% profit, was $40 a year , assuming 10 million people used it annually. In the long-term, 60 million people would probably need to take the drug preventatively to lower HIV levels significantly, they said.

Accounting for 30% profit seems reasonable to me.

Yet they’re selling it for 1000x the price.

I understand they need to recoup research costs, but…

I have no other words.